Guardant and Flatiron Team Up to Accelerate Development of Cancer Therapies

Guardant Health and Flatiron Health are teaming up to build a cloud-based information platform to support the accelerated development of targeted therapies for cancer.

The partnership will look to combine genomic data from Guardant Health’s Guardant360 liquid biopsy platform with clinical data from the FlatironHealth OncologyCloudTM platform.

The platform will enable companies to uncover new molecular targets, expand clinical indications and longitudinally follow patients and their progress over time.

Guardant Health CEO and co-founder Helmy Eltoukhy says the collaboration will accelerate timelines for drug development and enable new treatment options for millions of cancer patients. — Michael Cipriano